Loading...
•
Dec 31, 2023
Dynavax Q4 2023 Earnings Report
Dynavax reported financial results for the fourth quarter and full year ended December 31, 2023.
Key Takeaways
Dynavax reported HEPLISAV-B vaccine net product revenue of $51.1 million for Q4 2023, a 46% increase compared to Q4 2022. The company's cash position increased to $742.3 million at year-end and anticipates being cash flow positive for the full year 2024. They expect 2024 to be an important year in building a vaccine portfolio of best-in-class products.
HEPLISAV-B vaccine net product revenue for Q4 2023 was $51.1 million, representing a 46% year-over-year growth.
HEPLISAV-B total market share in the U.S. increased to approximately 42% at the end of 2023.
Dynavax submitted an Investigational New Drug Application (IND) to the U.S. FDA to support initiation of a Phase 1/2 trial of Z-1018 in the first half of 2024.
GAAP net income was $0.2 million, or less than $0.01 per share in Q4 2023.
Revenue by Segment
Forward Guidance
Dynavax provided full year 2024 financial guidance, based on the Company’s current operating plan.
Positive Outlook
- HEPLISAV-B net product revenue between approximately $265 - $280 million, including approximately $3 million in ex-U.S. sales through commercialization agreement with Bavarian Nordic in Germany
- HEPLISAV-B gross margin of approximately 80% for full year 2024
- Research and development expenses between approximately $60 - $75 million
- Selling, general and administrative expenses between approximately $160 - $180 million
- Expect to be cash flow positive for full year ended December 31, 2024
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...